Taiwan Advanced Nanotech Inc. (6797) Fair Value & Analysis
Healthcare · TW · Market cap 394M TWD
Strengths
Risks
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 12 days ago
Fair value updated Aug 13, 2026, revised from 28.77 TWD to 27.03 TWD (−6.0%) since Jul 23, 2026. Share price −7.3% over the past month.
Below-average quality, trading 55% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (24.96 TWD). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 11.80 TWD – 235.22 TWD · fair‑value band 24.96 TWD – 30.14 TWD · the 12.10 TWD price screens below the 27.03 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Taiwan Advanced Nanotech Inc. (6797) currently trades at 12.10 TWD, while our model-based Fair Value estimate is 27.03 TWD, implying the stock looks roughly 123.4% undervalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at 154M TWD. Revenue declined 16.9% year over year. It earns a return on equity of -25.5%. Net debt stands at 36.8M TWD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 24.96 TWD (bear case) to 30.14 TWD (bull case); at 12.10 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 1% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at 123%, 6797 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Dividend Discount (25.47 TWD) versus Asset-Based (17.21 TWD). Highest evidence: Gordon GGM (70).
Notify me when 6797 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 40 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan.
Full company description
Taiwan Advanced Nanotech Inc. engages in the development, manufacturing, and sales of various functional nanoparticles and automated nucleic acid extraction equipment in Taiwan. The company provides automated extraction instruments; nucleic acid extraction kit that extracts DNA/RNA from samples of blood, cell, tissue, plant, bacteria, virus, etc.; consumables, such as spin tips and deep well plates; filling line systems; and molecular biology reagents. It also provides OEM/ODM services. The company was founded in 2004 and is based in Taoyuan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Taiwan Advanced Nanotech Inc. reported revenue of 154M TWD in FY2025 versus 1.9B TWD in FY2021, a compound −46.8%/yr. Reported net income was −227M TWD in FY2025.
Watch 6797: get an alert when its fair value changes →
Peer Group
Medical Devices · 363 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $327.70 | $186.28 | -43% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $50.37 | $38.44 | -24% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Siemens Healthineers AG SHL | €39.04 | €33.87 | -13% |
| DexCom, Inc DXCM | $90.80 | $38.95 | -57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare Taiwan Advanced Nanotech Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Taiwan Advanced Nanotech Inc. (6797) overvalued or undervalued?
What is the fair value of 6797?
What is the quality score of 6797?
What is the revenue of Taiwan Advanced Nanotech Inc. (6797)?
What is the net profit margin of 6797?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Taiwan Advanced Nanotech Inc. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.